NovaBiotics at World Antimicrobial Resistance Congress, Washington
13/09/2017
NovaBiotics at ASM/ESCMID Conference
31/08/2017
NovaBiotics at the 7th International Meeting on Antimicrobial Peptides
21/08/2017
NovaBiotics Chief Executive responds to Public Health England warning on Candida auris fungus
16/08/2017
City doctor at the heart of a global superbug battle
04/08/2017
NovaBiotics featured on STV News
04/08/2017
New Drug Kills MRSA – including strains with antibiotic resistance
03/08/2017
50th patient recruited for CARE- CF-1 Lynovex clinical study
01/08/2017
NovaBiotics’ novel antimicrobial Luminaderm highly effective against Multi drug resistant MRSA
16/06/2017
NovaBiotics participating in BIO 2017 in San Diego
15/06/2017
NovaBiotics at European Cystic Fibrosis Conference in Seville
06/06/2017
NovaBiotics at American Society for Microbiology
26/05/2017
30 subjects now randomised in Lynovex CARE-CF-1 trial
10/05/2017
NovaBiotics contribution to ECCMID 2017
13/04/2017
NovaBiotics Quality Management System Achieves ISO 9001 certification
11/04/2017
NovaBiotics to host live Twitter Lynovex Q&A
24/03/2017
NovaBiotics Chief Executive Addresses 'Superbugs & Superdrugs' Conference on Antimicrobial Drug Discovery
21/03/2017
NovaBiotics CEO to speak at 19th Superbugs & Superdrugs Conference
17/03/2017
NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
03/03/2017
NovaBiotics CEO to speak at 10th Berlin Conference on Life Sciences
21/02/2017
NovaBiotics at ECCMID 2017
25/01/2017
NovaBiotics CEO featured as one of 15 women leading in European Biotech
18/01/2017
NovaBiotics announces first patients dosed in Lynovex clinical study
16/01/2017
